Medical Devices

With its Moda-flx system cleared by the FDA, Diality hires M&A expert Peter Donato to navigate the path to commercialization in the $92B dialysis market.

A new report shows patients are rejecting 'overdone' looks for subtle, strategic care, driven by Ozempic, menopause, and a desire for authenticity.

The Emerging Growth Conference showcases tomorrow's innovators. But with paid presentations, investors must look past the hype to find true value.

A new partnership brings an FDA-designated breakthrough device to more patients, fueled by a key Medicare payment that could reshape the trauma market.

Beam Therapeutics is set to announce its 2025 financial results and a new liver-targeted therapy, a key moment for its base editing platform and investors.

With promising data in cancer and eczema, all eyes are on Corvus Pharmaceuticals as it presents its lead drug at a major healthcare conference this week.

Biomerics appoints manufacturing veteran Tyler Reed to lead its Micro Metals Division, a strategic move to optimize recent acquisitions and dominate the market.

A Korean firm says it can cure 34 diseases using cells from cloned embryos, walking a fine line between a medical breakthrough and a bioethical taboo.

ZEISS launches Collaborative Care, a cloud-based solution to connect optometrists and ophthalmologists, streamlining referrals and data sharing for better care.

With strong growth in key sectors but weakness in others, Plexus management faces a pivotal moment at the upcoming Raymond James investor conference.

Mopec Group appoints Scott Nudelman to lead its new Certified Service division, a strategic move to boost lab uptime and gain a competitive edge.

With its stock under pressure, Geron will face investors to defend its RYTELO sales strategy and address delays in its pivotal myelofibrosis trial.

BioVie faces a pivotal moment, touting breakthrough drugs for Alzheimer's and cirrhosis while navigating clinical setbacks and financial pressures.

At a key industry summit, Sutro Biopharma showcases its next-gen ADC platform, designed to overcome treatment resistance with "supercharged" dual-payload drugs.

As Lyell presents at three major investor conferences, the biotech's pipeline, financial health, and future in cancer therapy are under scrutiny.

As cardiovascular disease affects nearly half of US adults, experts are urging a shift to existing, life-saving therapies that are widely ignored.

Verrica Pharmaceuticals heads to a key investor conference with strong YCANTH sales, a promising pipeline for warts and skin cancer, and high expectations.

With a novel skin drug launched, Pelthos Therapeutics heads to a key conference. Can its focused strategy convince Wall Street of its blockbuster potential?

A brief delay in Avidity's stockholder vote signals the final, complex steps before its acquisition by Novartis and the launch of a new spin-off.

ITF Therapeutics will unveil 10 new data presentations on its Duchenne therapy, DUVYZAT, offering critical new insights on long-term safety and efficacy.